Primary Outcomes

Measure: Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations

Time: Single Ascending Dose (SAD) Phase 119 days

---

Measure: Safety endpoints, including incidence of Adverse Event (AEs), serious AEs, AEs leading to discontinuation or death, as well as marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, and physical examinations

Time: Multiple Ascending Dose (MAD) phase 148 days

---

Secondary Outcomes

Measure: Maximum observed serum concentration (Cmax) for SAD and MAD

Time: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

---

Measure: Time of maximum observed serum concentration (Tmax) for SAD and MAD

Time: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

---

Measure: Serum concentration 168 h post dose (C(168H)) for SAD and MAD

Time: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

---

Measure: Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) for SAD

Time: SAD phase: Day1 to Day 91

---

Measure: Area under the serum concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) for SAD

Time: SAD phase: Day1 to Day 91

---

Measure: Apparent total body clearance (CLT/F) for SAD

Time: SAD phase: Day1 to Day 91

---

Measure: Volume of distribution of terminal phase (if IV and if multi-exponential decline) (Vz/F) for SAD

Time: SAD phase: Day1 to Day 91

---

Measure: Half life (T-Half) for SAD and MAD

Time: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

---

Measure: Serum concentration 336 h post dose (C(336H)) for SAD and MAD

Time: SAD phase: Day1 to Day 91, MAD phase: Day 1 to Day 120

---

Measure: Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff_AUC) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: Area under the concentration-time curve in one dosing interval (AUC(TAU)) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: Degree of Fluctuation or Fluctuation Index (DF) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: Average concentration over a dosing interval (Css-Avg) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: AUC Accumulation Index; ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI AUC) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: Cmax Accumulation Index; ratio of Cmax at steady-state to Cmax after the first dose (AI Cmax) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: C(168H) Accumulation Index; ratio of C168H at steady-state to C168H after the first dose (AI C168H) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: C(336H) Accumulation Index; ratio of C(336H) at steady-state to C(336H) after the first dose (AI 336H) for MAD

Time: MAD phase: Day 1 to Day 120

---

Measure: Immunogenicity of single and multiple doses of BMS-986089 will be measured by testing for the presence of ADAs for SAD and MAD

Time: 30 days

---

Measure: The pharmacodynamic effect of single and multiple doses of BMS-986089 on free myostatin, total myostatin (pre-dose only), and myostatin-drug complex will be assessed by measuring these biomarkers for SAD and MAD

Time: 30 days

---